WHAT IS CLAIMED IS:

1. A glycopeptide substituted at the C-terminus and/or the R-terminus with a substituent that comprises one or more saccharide groups and a carboxy group; or a pharmaceutically acceptable salt, or stereoisomer, or prodrug thereof;

provided the glycopeptide is not a compound of formula II:



(II)

a) wherein R^3 is N-(2-amino-2-deoxygluconic acid); R^5 is hydrogen; R^{19} is hydrogen; and R^{20} is -NH-CH_2CH_2-NH-$(CH_2)_9CH_3$; or

b) wherein R^3 is OH; R^5 is -CH_2-N-(2-amino-2-deoxygluconic acid); R^{19} is hydrogen; and R^{20} is -CH_2CH_2-NH-$(CH_2)_9CH_3$.

2. The glycopeptide of claim 1 which is substituted at the C-terminus and the R-terminus with a substituent that comprises a saccharide and a carboxy group.

3. The glycopeptide of claim 1 which is substituted at the C-terminus with a substituent that comprises a saccharide and a carboxy group.

4. The glycopeptide of claim 1 which is substituted at the R-terminus with a substituent that comprises a saccharide group and a carboxy group.

5. The glycopeptide of claim 3 wherein the substituent that comprises a saccharide and a carboxy group has the formula $-N(R^w)-R^y-R^x$; wherein R^w is hydrogen or alkyl; R^y is substituted alkylene, which is substituted with a carboxy group; and R^x is a saccharide.

6. The glycopeptide of claim 3 wherein the substituent is a substituent of formula III:



(III)

wherein one of R^g and R^h is a saccharide, and the other of R^g and R^h is OH.

7. The glycopeptide of claim 4 wherein the substituent that comprises a saccharide and a carboxy group has the formula $-CH_2N(R^w)-R^y-R^x$; wherein R^w is hydrogen or

alkyl; R^y is substituted alkylene, which is substituted with a carboxy group; and R^x is a saccharide.

8. The glycopeptide of claim 4 wherein the substituent is a substituent of formula IV:



wherein one of R^m and R^n is a saccharide, and the other is OH.

9. The glycopeptide of claim 4 wherein the substituent is a substituent of formula V:



(V)

10. The glycopeptide of claim 1 which is a compound of formula I:



(I)

wherein:

R^1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-R^a-Y-R^b-(Z)_x$; or R^1 is a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$, R^f, $-C(O)R^f$, or $-C(O)-R^a-Y-R^b-(Z)_x$;

R^2 is hydrogen or a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$, R^f, $-C(O)R^f$, or $-C(O)-R^a-Y-R^b-(Z)_x$;

R^3 is $-OR^c$, $-NR^cR^c$, $-O-R^a-Y-R^b-(Z)_x$, $-NR^c-R^a-Y-R^b-(Z)_x$, $-NR^cR^e$, or $-O-R^e$; or R^3 is a substituent that comprises a saccharide group and a carboxy group;

R^4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, $-C(O)R^d$ and

a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$, R^f, $-C(O)R^f$, or $-C(O)-R^a-Y-R^b-(Z)_x$;

R^5 is selected from the group consisting of hydrogen, halo, $-CH(R^c)-NR^cR^c$, $-CH(R^c)-NR^cR^c$, $-CH(R^c)-NR^c-R^a-Y-R^b-(Z)_x$, $-CH(R^c)-R^x$, $-CH(R^c)-NR^c-R^a-C(=O)-R^x$, or R^5 is substituent that comprises a saccharide group and a carboxy group;

R^6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, $-C(O)R^d$ and a saccharide group optionally substituted with $-NR^c-R^a-Y-R^b-(Z)_x$, or R^5 and R^6 can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with $-NR^c-R^a-Y-R^b-(Z)_x$;

R^7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, $-R^a-Y-R^b-(Z)_x$, and $-C(O)R^d$;

R^8 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^{10} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; or R^8 and R^{10} are joined to form $-Ar^1-O-Ar^2-$, where Ar^1 and Ar^2 are independently arylene or heteroarylene;

R^{11} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic, or

R^{10} and R^{11} are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;

R^{12} is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, $-C(O)R^d$, $-C(NH)R^d$, $-C(O)NR^cR^c$, $-C(O)OR^d$, $-C(NH)NR^cR^c$ and $-R^a-Y-R^b-(Z)_x$, or R^{11} and R^{12} are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;

R^{13} is selected from the group consisting of hydrogen or $-OR^{14}$;

R^{14} is selected from hydrogen, $-C(O)R^d$ and a saccharide group;

each R^a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;

each R^b is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R^b is not a covalent bond when Z is hydrogen;

each R^c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and $-C(O)R^d$;

each R^d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R^e is a saccharide group;

each R^f is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, or heterocyclic;

R^x is N-linked amino saccharide or an N-linked heterocycle;

X^1, X^2 and X^3 are independently selected from hydrogen or chloro;

each Y is independently selected from the group consisting of oxygen, sulfur, -S-S-, $-NR^c-$, -S(O)-, $-SO_2-$, $-NR^cC(O)-$, $-OSO_2-$, -OC(O)-, $-NR^cSO_2-$, $-C(O)NR^c-$, -C(O)O-, $-SO_2NR^c-$, $-SO_2O-$, $-P(O)(OR^c)O-$, $-P(O)(OR^c)NR^c-$, $-OP(O)(OR^c)O-$, $-OP(O)(OR^c)NR^c-$, -OC(O)O-, $-NR^cC(O)O-$, $-NR^cC(O)NR^c-$, $-OC(O)NR^c-$, -C(=O)-, and $-NR^cSO_2NR^c-$;

each *Z* is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

n is 0, 1 or 2; and

x is 1 or 2;

or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof;

provided at least one of R^3 and R^5 is a substituent that comprises a saccharide group and a carboxy group.

11. The glycopeptide of claim 10 wherein R^1 is a saccharide group optionally substituted with $-R^a-Y-R^b-(Z)_x$, R^f, $-C(O)R^f$, or $-C(O)-R^a-Y-R^b-(Z)$.

12. The glycopeptide of claim 10 wherein R^1 is a saccharide group of the formula:



wherein R^{15} is $-R^a-Y-R^b-(Z)_x$, R^f, $-C(O)R^f$, or $-C(O)-R^a-Y-R^b-(Z)_x$; and R^{16} is hydrogen or methyl.

13. The glycopeptide of claim 10 wherein R^3 has the formula $-N(R^w)-R^y-R^x$; wherein R^w is hydrogen or alkyl; R^y is substituted alkylene, which is substituted with a carboxy group; and R^x is a saccharide.

14. The glycopeptide of claim 10 wherein R^5 is a substituent that comprises a saccharide group and a carboxy group having the formula $-CH_2N(R^w)-R^y-R^x$; wherein R^w is hydrogen or alkyl; R^y is substituted alkylene, which is substituted with a carboxy group; and R^x is a saccharide.

15. The glycopeptide of claim 10 which is a compound of formula II:



(II)

wherein:

R^{19} is hydrogen;

R^{20} is $-R^a-Y-R^b-(Z)_x$, R^f, $-C(O)R^f$, or $-C(O)-R^a-Y-R^b-(Z)_x$; and

R^a, Y, R^b, Z, x, R^f, R^3, and R^5 have the values defined in claim 10;

or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof;

provided at least one of R^3 and R^5 is a substituent that comprises a saccharide group and a carboxy group.

16. The glycopeptide of claim 15 wherein R^3 has the formula $-N(R^w)-R^y-R^x$; wherein R^w is hydrogen or alkyl; R^y is substituted alkylene, which is substituted with a carboxy group; and R^x is a saccharide.

17. The glycopeptide of claim 16 wherein R^3 is of the formula III:



(III)

wherein one of R^g and R^h is a saccharide, and the other of R^g and R^h is OH.

18. The glycopeptide of claim 15 wherein R^5 is a substituent that comprises a saccharide group and a carboxy group having the formula $-CH_2N(R^w)-R^y-R^x$; wherein R^w is hydrogen or alkyl; R^y is substituted alkylene, which is substituted with at least one carboxy group; and R^x is a saccharide, and R^5 is -OH.

19. The glycopeptide of claim 18 wherein R^5 is of the formula IV:



wherein one of R^m and R^n is a saccharide, and the other is OH.

20. The glycopeptide of claim 15 wherein R^5 is of the formula V:



(V)

21. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1.

22. The pharmaceutical composition of Claim 21, which comprises a cyclodextrin.

23. A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a glycopeptide of claim 1.

24. A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of

a glycopeptide of claim 10.

25. A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a glycopeptide of claim 15.

26. A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a therapeutically effective amount of a pharmaceutical composition of claim 21.